RIGL
Rigel Pharmaceuticals Inc
NASDAQ · Biotechnology
$34.15
+0.93 (+2.80%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 183.98M | 173.06M | 391.65M | 385.25M | 314.84M |
| Net Income | 17.94M | 15.19M | -57,293,222 | -63,461,041 | -63,887,744 |
| EPS | — | — | — | — | — |
| Profit Margin | 9.8% | 9.3% | -14.6% | -16.5% | -20.3% |
| Rev Growth | +6.3% | +6.3% | +12.4% | +12.7% | +12.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 293.75M | 293.75M | 199.91M | 244.43M | 243.77M |
| Total Equity | 16.18M | 16.18M | 324.24M | 293.70M | 288.30M |
| D/E Ratio | 18.15 | 18.15 | 0.62 | 0.83 | 0.85 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 27.11M | 24.23M | -94,057,035 | -108,813,206 | -86,400,635 |
| Free Cash Flow | — | — | -78,875,103 | -71,858,369 | -72,598,863 |